UnitedHealth Group (UNH) Joins Zacks Strong Buy List As Undervalued Narrative Builds
UnitedHealth Group (UNH) has drawn fresh attention after being added to the Zacks Rank #1 (Strong Buy) list, following an increase in the Zacks Consensus Estimate for current year earnings.
See our latest analysis for UnitedHealth Group.
UnitedHealth Group's short term share price performance has been weak, with a 30 day share price return down 9.55%. However, the year to date share price return of 15.97% and 1 year total shareholder return of 30.30% point to still positive overall momentum as investors weigh earnings revisions, dividend continuity and ongoing cost pressures.
If you are comparing UnitedHealth Group with other opportunities in the sector, this could be a good moment to look at a curated list of healthcare and insurance peers using our healthcare focused AI stock screener, starting with 41 healthcare AI stocks.
UnitedHealth Group now trades at a clear discount to both analyst targets and some intrinsic value estimates after a recent pullback. Is that a reasonable cushion for its cost and margin risks, or is it a sign the market remains cautious?
Most Popular Narrative: 17.9% Undervalued
The most followed narrative currently points to a fair value of $475.23 for UnitedHealth Group compared with the last close of $390.11. That gap rests on specific views about Medicare, Optum and the impact of technology spending.
The company is addressing unanticipated changes in Medicare membership profiles which impacted 2025 revenue. They are taking measures to ensure complex patients engage in clinical and value-based programs, which should help stabilize and potentially increase future revenue.
Want to see what turns that engagement plan into a higher valuation for UnitedHealth Group? The narrative leans heavily on a particular mix of revenue growth, margin rebuild and a future earnings multiple that is usually reserved for faster growing sectors. Curious which assumptions actually carry most of the weight in that fair value.
Result: Fair Value of $475.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, UnitedHealth Group still faces meaningful risks, including execution on the new CMS risk model and potential policy or funding shifts that pressure Medicare Advantage margins.
Find out about the key risks to this UnitedHealth Group narrative.
Next Steps
The mixed tone of this UnitedHealth Group update shows both concern and optimism, so consider reviewing the underlying data soon and forming your own view using the 5 key rewards and 1 important warning sign.
Looking for more investment ideas beyond UnitedHealth Group?
If you are serious about building a stronger portfolio, do not stop at UnitedHealth Group. Use the Simply Wall Street Screener to uncover fresh opportunities that match your goals.
- Target potential mispricing by scanning for companies that combine quality fundamentals with attractive valuations through the 48 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with higher yields and resilient payout histories using the 12 dividend fortresses.
- Prioritise capital preservation by focusing on companies with more resilient profiles and lower risk scores via the 78 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com